Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02164539 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
338
Enrollment target
20
Study locations

NCT02164539 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 338 participants, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02164539, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
338 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide in combination with fluticasone furoate compared with fluticasone furoate monotherapy in chronic obstructive pulmonary disease participants with an asthmatic component. The fluticasone furoate/umeclidinium bromide treatments will also be compared to the once-daily inhaled corticosteroid/long-acting beta agonist combination fluticasone furoate/vilanterol.

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG FF
  • DRUG UMEC
  • DRUG VI

Study Locations (20)

South Carolina

  • GSK Investigational Site - Gaffney
  • GSK Investigational Site - Greenville
  • GSK Investigational Site - Rock Hill
  • GSK Investigational Site - Spartanburg
  • GSK Investigational Site - Union

California

  • GSK Investigational Site - Newport Beach
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - Upland

Other

  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Mendoza

Louisiana

  • GSK Investigational Site - Sunset

Minnesota

  • GSK Investigational Site - Minneapolis

North Carolina

  • GSK Investigational Site - Charlotte

Ohio

  • GSK Investigational Site - Cincinnati

Oregon

  • GSK Investigational Site - Medford

Trial Details

FieldValue
Enrollment Target 338 participants
Start Date 2014-07-01
Est. Completion 2015-07-18
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02164539

The ClinicalTrials.gov registry entry for NCT02164539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (67% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which FF is the first listed.

NCT02164539 reports 20 study locations spanning 13 distinct geographic areas - top geographies include South Carolina, California, Other.

Frequently Asked Questions

What is clinical trial NCT02164539 about?

NCT02164539 is a clinical study titled "Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component". The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide in combination with fluticasone furoate compared with fluticasone furoate monotherapy in chronic obstructive pulmonary disease participants with an asthmatic component. The fluticasone furoate/umeclidinium ...

What is the current status of trial NCT02164539?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2014-07-01. Estimated completion is 2015-07-18.

What conditions does trial NCT02164539 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT02164539?

The interventions under investigation include: FF (DRUG), UMEC (DRUG), VI (DRUG).

Who is sponsoring clinical trial NCT02164539?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02164539 being conducted?

This trial has 20 study locations across California, Louisiana, Minnesota, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.